swapnil hiremath

July 8, 2024

Background

Mapping the course of rare renal diseases with RaDaR

swapnil hiremath

July 8, 2024

Background

Mapping the course of rare renal diseases with RaDaR

This week, we will discuss the RaDaR study. Does rare mean kidney failure occurs rarely? What are rare diseases? Do we see them in children more than adults? All this and more!

Jade Teakell

April 22, 2024

Background

Shedding Light on the Dense Matter of C3 Glomerulopathy

Jade Teakell

April 22, 2024

Background

Shedding Light on the Dense Matter of C3 Glomerulopathy

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

swapnil hiremath

November 28, 2023

Background

Optimizing “Sparse” Treatments for FSGS

swapnil hiremath

November 28, 2023

Background

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

swapnil hiremath

May 23, 2023

Background

SPARE a Thought for SPARSENTAN?

swapnil hiremath

May 23, 2023

Background

This week, we will discuss another IgA Nephropathy trial - Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.

swapnil hiremath

March 28, 2023

Background

MMF in IgA: Inching into the MAINstream?

swapnil hiremath

March 28, 2023

Background

MMF in IgA: Inching into the MAINstream?

This week, we will discuss the MAIN trial of MMF monotherapy in IgA Nephropathy. Pairs nicely with the NephMadness IgA Region discussion!

swapnil hiremath

January 10, 2023

Background

NefIgArdians of The Glomerular Galaxy

swapnil hiremath

January 10, 2023

Background

This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy - should it upstage humble prednisone?

Anna Gaddy

November 16, 2021

Commentary

2021 KDIGO Updates for Glomerular Disease: The Visual Abstract

Anna Gaddy

November 16, 2021

Commentary

This update was too big for just one slide! Michael Turk produced two Visual Primers to help you understand the 2021 GN changes at-a-glance.

swapnil hiremath

January 12, 2021

Background

Ponticelli still sparkles in Membranous

swapnil hiremath

January 12, 2021

Background

Was MENTOR the final word for Rituximab in Membranous Nephropathy? Not so. We discuss STARMEN this week which compared sequential tacrolimus- rituximab with the Ponticelli protocol.

swapnil hiremath

April 6, 2020

Background

Minimal Role for Steroids in Minimal Change Disease?

swapnil hiremath

April 6, 2020

Background

Minimal Role for Steroids in Minimal Change Disease?

Steroids are the mainstay of minimal change. Or are they? Lets explore an RCT that bravely challenges the status quo of steroids with tacrolimus monotherapy

swapnil hiremath

July 8, 2019

Background

MENTOR: Is Rituximab Ripened enough for Membranous?

swapnil hiremath

July 8, 2019

Background

MENTOR: Is Rituximab Ripened enough for Membranous?

This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy

swapnil hiremath

May 28, 2019

Background

Risk Stratifying A Heterogeneous Entity: IgA Nephropathy

swapnil hiremath

May 28, 2019

Background

Risk Stratifying A Heterogeneous Entity: IgA Nephropathy

This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.

swapnil hiremath

August 28, 2017

Background

IgA Nephropathy: Testing Steroids Again

swapnil hiremath

August 28, 2017

Background

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?